Anti-Scribble Antibody

220 kDa

Scribble is a tumor suppressor marker first discovered in Drosophila that has been implicated in the control of cell proliferation, polarity, invasion, and metastasis (Humbert, et al, 2003). Mammalian Scribble expresses basolateral staining in epithelial tissue and highly polarized expression in T lymphocytes (Dow, et al, 2003) (Ludford-Menting, et al, 2005), and plays an essential role in the regulation of the polarity specifically involved in directed epithelial migration. Altered expression of human Scribble is associated with invasive epithelial cancers, however, its role in tumour development remains unclear (Dow, et al, 2007).

Epitope: PDZ2 domain of Scribble

GST-tagged fusion protein corresponding to the PDZ2 domain of Scribble

Research Sub Category
Tumor Markers

Cytoskeleton

This Anti-Scribble Antibody is validated for use in WB for the detection of Scribble.

Suggested dilutions:
Western blot: 0.2 µg (1:2000)

Predicted to cross react with mouse based on sequence homology. Reactivity with other species has not been tested.

Format: Purified

Purified in PBS containing with 0.05% NaN3.

Maintain at 2-8°C for up to 1 year after date of receipt.

Routinely evaluated by Western blot on HeLa cell lysates.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

GenBank is a registered trademark of United States Department of Health and Human Services